The hearing on the Notice of Proposed Rulemaking for the rescheduling of “marijuana” commenced on June 29, 2026 and will end tomorrow, July 15th. The Government brought two witnesses to the stand on the first day, and then seven prohibitionist organizations had the floor for the remaining seven days of the hearing. As I discussed
The DEA’s marijuana rescheduling hearing continues to raise important questions for cannabis businesses, investors, and the industry as a whole. If you’re trying to keep up with where things stand and what may come next, this upcoming MJBizDaily webinar is worth your time. Harris Sliwoski attorney Jason Adelstone will join a panel of industry professionals
Until last week, federal law prohibited marijuana users from owning or possessing firearms, even in states where marijuana is legal. In recent years, we have covered the differing opinions by federal courts challenging this status quo. On June 18, 2026, the Supreme Court held in a 9-0 decision in U.S. v. Hemani that 18 U.S.C.
On April 28, 2026, Acting Attorney General Blanche (“AG”) issued a notice of hearing concerning the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). The notice replaced the hearing that began in December 2024 (“2024 Hearing”), which the AG terminated upon issuing the new notice. The
The Washington State Liquor and Cannabis Board (LCB) published an interesting bulletin this Tuesday, June 16th. The bulletin finds that DEA’s final rule on medical marijuana rescheduling “does not appear to apply to Washington’s cannabis licensees, due to the statutory framework predominantly regulating recreational cannabis.” The word “predominantly” is doing a lot of work in
Harris Sliwoski attorney Jason Adelstone will present at the International Cannabis Bar Association’s (INCBA) Cannabis Law Institute 2026, taking place June 17–18 in Chicago and hosted by Northwestern Pritzker School of Law. Jason will join Adi Rozenfeld of Herzog Fox & Neeman and Sahar Ayinehsazian of A.Y. Strauss for a panel discussion titled: Beyond Borders:
With just over two weeks until DEA’s expedited processing deadline for state legal operators to apply for DEA registration, several petitioners litigating the legality of the DEA’s final rule have filed a motion to stay DEA’s final rule in the D.C. Circuit (“Motion”). The Motion was brought by the National Drug and Alcohol Screening Association,
5月22日，内布拉斯加州、印第安纳州和路易斯安那州向美国哥伦比亚特区巡回上诉法院（“DC巡回法院”）提交了复审请愿书，对代理司法部长（“AG”）将美国食品药品监督管理局（FDA）批准且经各州许可的大麻列入《受控物质法》（“CSA”）第三类受控物质的最终行政决定提出异议。DC
自代理总检察长托德·布兰奇宣布将州内合法的医用大麻重新归类为第三类受控物质以来，相关评论便层出不穷——激进观点、末日论者以及自诩的专家们纷纷在领英上发表相互矛盾的解读。其中大部分内容纯属揣测、言过其实且缺乏依据。本文将拨开迷雾，针对我收到的各类疑问作出回应
对于持有州政府执照的医用大麻经营者而言，一个机会有限却可能带来变革的窗口已经开启——这将有助于您的企业为未来的州际乃至全球贸易做好准备。尽管代理总检察长的重新分类令可能会面临法律挑战，但眼下的现实是：您有60天的时间采取行动。截至昨天，即4月28日，
